
|Videos|June 11, 2019
Dr. Owonikoko on Talazoparib in HRRD-Positive Stage IV Squamous Cell Lung Cancer
Author(s)Taofeek K. Owonikoko, MD, PhD
Cancer Network spoke with Taofeek Kunle Owonikoko, MD, PhD, of Emory University, about talazoparib for patients with HRRD-positive stage IV squamous cell lung cancer.
Advertisement
Cancer Network spoke with Taofeek Kunle Owonikoko, MD, PhD, a professor in the Department of Hematology and Medical Oncology at Emory University, about the results of the phase II study he led that were presented at ASCO 2019. The research focused on the efficaacy of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD)-positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
2
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
3
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
4
Navigating New Horizons in Neuroendocrine Prostate Cancer
5























































